Shots:
BMS has entered into a definitive agreement to acquire Orbital, strengthening & diversifying its cell therapy portfolio
As per the deal, BMS will acquire Orbital, incl. its asset, OTX-201 & RNA platform, in an all-cash transaction of $1.5B
OTX-201 is a preclinical circular RNA therapy encoding a CD19 CAR for in vivo expression delivered via…
